🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Very proud of our own Saad Atiq National Cancer Institute senior fellow presenting data on the Prevalence of Histology-Agnostic Biomarkers in Pure Squamous Cell Carcinomas of the #Bladder showing 1/3 of patients with TMB-High ASCO #ASCO25 Caris Life Sciences

Our ANZUP #PCRMIB poster featured at #ASCO25. Well done to DrAndrewWeickhardt and the entire team for this important #bladdercancer study Cancer Australia & #BaCT (Centre for Biostatistics and Clinical Trials) Peter Mac Cancer Centre #MSD Ian Davis

We are excited that Demitrios Dedousis, MD will soon be joining us as faculty in GU Onc & Genetics Cleveland Clinic MD after an excellent fellowship training by the very best at Fox Chase Cancer Center Elizabeth Plimack MD Namrata (Neena) Vijayvergia MD Jame Abraham, MD, FACP P.S. ‼️We are hiring! For anyone interested in a

Finally had a chance to listen to the discussion EVERYONE in the GU community is talking about via ASCO Virtual Meeting. One of the most thoughtful & eloquent discussions I have ever seen by Jacqueline T. Brown, MD Winship Cancer Institute of Emory University, summarizing excellent presentations from Michiel van der Heijden

Fantastic Women Leaders in Oncology (and allies) event at #asco25 - what a great panel and amazing energy in the room! Rachna Shroff, MD, MS, FASCO Women Leaders in Oncology Conquer Cancer, the ASCO Foundation ASCO

Golden selfie moment with the one and only Toni Choueiri, MD - an incredible mentor, brilliant mind, and cherished friend. Grateful as always for your support and guidance! 🙏✨ #ASCO25 Paulo G Bergerot

Congrats Nick James also on @Prof-Nick-James.bsky.social & team👉@asco #ASCO25 👉a prognostic digital pathology based AI score (ArteraAI) identifies pts with clinically high-risk #prostatecancer (non metastatic) 👉likely to benefit most from adding abiraterone to SOC OncoAlert UroToday.com Prostate Cancer Foundation

Congrats Alicia Morgans, MD, MPH for the outstanding talk ASCO #ASCO25 👉favorable health-related QOL reported by the pts in ph3 ARANOTE trial treated with darolutamide in mHSPC #prostatecancer 👇OncoAlert UroToday.com PCF Science @fredsaad

Congrats Andrew Armstrong for the 5-yr follow-up OS results from ph3 Arches trial in mHSPC #prostatecancer with enzalutamide ASCO #ASCO25 👉66% probability of survival at 5 yrs & 30% reduction of risk of death with enzalutamide👇OncoAlert UroToday.com PCF Science Arun Azad

More data from the ph3 Amplitude trial ASCO #ASCO25 👉trial design, safety, subsequent therapy, rPFS in subgroups Prostate Cancer Foundation UroToday.com OncoAlert

This is remarkable practice changing data in mHSPC! Congrats AttardLab Neeraj Agarwal, MD, FASCO & entire AMPLITUDE team!

Avelumab 1L maintenance vs best supportive care after platinum based chemo in advanced urothelial cancer; ⭐️Non-visceral mets: OS➡️31.4 vs 17.1 months (HR:0.6) and LN-only disease: OS➡️31.9 vs 22.7 months (HR:0.8) ⭐️Durable outcomes + manageable safety ➡️➡️still promising

The International Bladder Cancer Group (IBCG) is pleased to announce the #IBCG2025 Travel Award, designed to support outstanding fellows and early-career academic faculty who are committed to advancing the field of bladder cancer. For more information and to apply:

Adjuvant Nivolumab in MIUC – Real-World Data with a Focus on Disparities led by Alex Chehrazi-Raffle, MD A quick tweetorial 🧵 ⁉️ Can real-world outcomes of adjuvant nivolumab match those from clinical trials? And how does it perform in underrepresented groups? ➡️We evaluated 253 patients

Thrilled to wrap up final days of residency with 1st place at Resident Research Day Fairview IMRP ! Immense gratitude to Shilpa Gupta for her exceptional mentorship. Eager to begin my Hematology-Oncology fellowship UIC Heme Onc Fellowship !

Mary-Claire King to receive the Princesa de Asturias award in Spain for her work in genetics. She is known for identifying BRCA1 and BRCA2 and describing the Hereditary Breast and Ovarian Cancer Syndrome. This just one of her multiple contributions to science. ESMO - Eur. Oncology David Gillespie

“We know we need it. We don’t know how to control it.” John Marshall raises powerful questions about truth, trust, and the future of AI in oncology. How do we protect scientific integrity in an AI-driven world? 🎙️ Watch the latest #OncologyUnscripted episode for more:

Just in Clinical Cancer Research 👉Congrats Chadi Hage Chehade Umang Swami & GU Cancer Research Program @HuntsmanCancer team👉Poor outcomes w/ SOC Rx in mHSPC #prostatecancer w/HRRm in 637 real-world US pts👇 Flatiron Health Foundation Medicine Ryon Graf, PhD 👉 need to add PARPi 👉free link: bit.ly/3TsOw9i OncoAlert UroToday.com

🎥 #ASCO2025 In-Depth! Prof Shilpa Gupta & Prof Emmanuel on EV-302: ✔️75% CRs remain 2y later ✔️ Early toxicity management - no impact on efficacy 👀 Watch now bit.ly/4mLvOXR #MediMix #BladderCancer #UrothelialCancer #EV302

It is wonderful to be part of one of the cancer hospitals in the world as per ⁦Newsweek⁩ rankings.newsweek.com/americas-best-…